ISPC Quote, Financials, Valuation and Earnings

Delcath Systems has a net margin of -54.09% compared to iSpecimen's net margin of 16.64%. iSpecimen's return on equity of -118.86% beat Delcath Systems's return on equity of -251.36%.

iSpecimen has a consensus price target of --, signalling upside risk potential of 1900%. On the other hand Delcath Systems has an analysts' consensus of -- which suggests that it could grow by 93.94%. Given that iSpecimen has higher upside potential than Delcath Systems, analysts believe iSpecimen is more attractive than Delcath Systems.

iSpecimen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Delcath Systems has a beta of 0.851, suggesting its less volatile than the S&P 500 by 14.882%.

iSpecimen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iSpecimen pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

iSpecimen quarterly revenues are $2.7M, which are smaller than Delcath Systems quarterly revenues of $11.2M. iSpecimen's net income of -$1.4M is lower than Delcath Systems's net income of $1.9M. Notably, iSpecimen's price-to-earnings ratio is -- while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iSpecimen is 0.16x versus 13.18x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

23andMe Holding has a net margin of -54.09% compared to iSpecimen's net margin of -134.11%. iSpecimen's return on equity of -118.86% beat 23andMe Holding's return on equity of -214.19%.

iSpecimen has a consensus price target of --, signalling upside risk potential of 1900%. On the other hand 23andMe Holding has an analysts' consensus of -- which suggests that it could grow by 156.27%. Given that iSpecimen has higher upside potential than 23andMe Holding, analysts believe iSpecimen is more attractive than 23andMe Holding.

iSpecimen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison 23andMe Holding has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

iSpecimen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 23andMe Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iSpecimen pays -- of its earnings as a dividend. 23andMe Holding pays out -- of its earnings as a dividend.

iSpecimen quarterly revenues are $2.7M, which are smaller than 23andMe Holding quarterly revenues of $44.1M. iSpecimen's net income of -$1.4M is higher than 23andMe Holding's net income of -$59.1M. Notably, iSpecimen's price-to-earnings ratio is -- while 23andMe Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iSpecimen is 0.16x versus 0.32x for 23andMe Holding. Usually stocks with elevated PS ratios are considered overvalued.

Progyny has a net margin of -54.09% compared to iSpecimen's net margin of 3.64%. iSpecimen's return on equity of -118.86% beat Progyny's return on equity of 11.31%.

iSpecimen has a consensus price target of --, signalling upside risk potential of 1900%. On the other hand Progyny has an analysts' consensus of $30.22 which suggests that it could grow by 31.5%. Given that iSpecimen has higher upside potential than Progyny, analysts believe iSpecimen is more attractive than Progyny.

iSpecimen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Progyny has a beta of 1.350, suggesting its more volatile than the S&P 500 by 34.952%.

iSpecimen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Progyny offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iSpecimen pays -- of its earnings as a dividend. Progyny pays out -- of its earnings as a dividend.

iSpecimen quarterly revenues are $2.7M, which are smaller than Progyny quarterly revenues of $286.6M. iSpecimen's net income of -$1.4M is lower than Progyny's net income of $10.4M. Notably, iSpecimen's price-to-earnings ratio is -- while Progyny's PE ratio is 24.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iSpecimen is 0.16x versus 1.24x for Progyny. Usually stocks with elevated PS ratios are considered overvalued.

RadNet has a net margin of -54.09% compared to iSpecimen's net margin of 0.7%. iSpecimen's return on equity of -118.86% beat RadNet's return on equity of -0.45%.

iSpecimen has a consensus price target of --, signalling upside risk potential of 1900%. On the other hand RadNet has an analysts' consensus of $68.17 which suggests that it could grow by 23.91%. Given that iSpecimen has higher upside potential than RadNet, analysts believe iSpecimen is more attractive than RadNet.

iSpecimen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison RadNet has a beta of 1.768, suggesting its more volatile than the S&P 500 by 76.83%.

iSpecimen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RadNet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iSpecimen pays -- of its earnings as a dividend. RadNet pays out -- of its earnings as a dividend.

iSpecimen quarterly revenues are $2.7M, which are smaller than RadNet quarterly revenues of $461.1M. iSpecimen's net income of -$1.4M is lower than RadNet's net income of $3.2M. Notably, iSpecimen's price-to-earnings ratio is -- while RadNet's PE ratio is 444.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iSpecimen is 0.16x versus 2.94x for RadNet. Usually stocks with elevated PS ratios are considered overvalued.